Friday Jun 14
Digital Post Production
2013 BioProcess Theater Presentations Now Available on the BioProcess ...
BioProcess International announces the online publication of the complete set of BPI Theater podcasts presented during the 2013 BIO International Convention, 2225 April in Chicago, IL.
Friday Jun 14
Ongoing Clinical Trials Reveal Groundbreaking Results - Research...
Today, Wall Street Reports announced new research reports highlighting Alexion Pharmaceuticals, Inc. , BioMarin Pharmaceutical Inc. , Onyx Pharmaceuticals, Inc. , Questcor Pharmaceuticals, Inc. , and ImmunoGen, Inc. .
Mon Jun 10, 2013
Synta Pharmaceuticals Corp. (SNTA), VeriFone Systems Inc (PAY): 5 of Last Week's Biggest Losers
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.
Sun Jun 09, 2013
Now Available: ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review
ImmunoGen, Inc. is a biotechnology company. It develops anticancer therapeutics using its proprietary TAP technology.
Thu Jun 06, 2013
New Market Report: ImmunoGen, Inc. - Mergers & Acquisitions (M&A),...
Project Description: MarketLines' ImmunoGen, Inc. Mergers & Acquisitions , Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions , divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ImmunoGen, Inc. since January 2007.
Tue Jun 04, 2013
This Metric Says You Are Smart to Sell ImmunoGen, Inc.
The number of bullish hedge fund bets stayed the same which is a slightly negative development in our experience At the moment, there are tons of gauges market participants can use to track the equity markets.
Mon Jun 03, 2013
First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s...
ImmunoGen, Inc. , a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.
Thu May 30, 2013
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer cell-killing agents specifically to tumor cells.